NYSE:PFE Earnings and Revenue History November 11th 2025 How Do Unusual Items Influence Profit? To properly understand Pfizer ...

Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

Pfizer’s Q3 2025 earnings fell despite beating estimates. Weak growth and a stagnant outlook keep PFE stock a Hold.

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the ...

Pfizer files lawsuits against Novo over $9B Metsera bid, challenging 30-month timeline. Court hearing Tuesday as deadline ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

“Pfizer beat the numbers and people just yawned. Oh my god the group is so challenged. “But we’re looking for that big win ...

Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could ...

Revenue reported by Pfizer in Q3 2025 came in at $16.7 billion, which was another beat compared to the analysts’ estimate of ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...

In the latest close session, Pfizer (PFE) was down 1.09% at $24.50. This move lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow experienced a rise of 0.34%, and the technology-dominated ...